CA-KINETIC-TECHNOLOGIES
15.6.2022 11:02:12 CEST | Business Wire | Press release
Kinetic Technologies, a high-performance analog and mixed-signal semiconductor company focused on developing power management and protection solutions for consumer, communications, industrial, automotive and enterprise markets, announced today the Company has completed the acquisition of certain assets pursuant to an asset purchase agreement with Gain Semiconductor Incorporated. The acquisition was completed on May 6, 2022. Terms of the asset transaction include the transfer of intellectual property consisting of patents, copyrights, and industry knowledge plus seasoned motor control industry professionals.
By acquiring Gain’s Pure Sinusoidal Drive patented technology Puresine™, Kinetic Technologies is positioned to bring superior motor and motion control to market. This technology converts standard 3-wire motor control and 6-wire advanced motor control technology into a new class of motor control solutions by maximizing electrical efficiency. Higher efficiency reduces the motor’s power needed to operate, offering a way to design a smaller, lighter-weight motor.
“Increasing motor control electrical efficiency paints a new canvas to deliver a greener environment for our future. By leveraging Kinetic Technologies’ proven manufacturing ability and technical excellence, we believe our motor control technology is now positioned to advance to the next phase in production and advanced product development,” stated Jeff Gray, GM of Motor Control at Kinetic Technologies, and previous CEO of Gain Semiconductor.
“The electronic motor control space enables Kinetic Technologies to expand its served addressable market further into consumer whitegoods, automotive and industrial. The introduction of motor controller products will diversify our offerings and broaden our portfolio with commercially synergistic products. We believe this transaction will allow us to enter new markets, work with new customers, and expand our business with existing customers by selling additional high-performance products,” said Kin Shum, CEO of Kinetic Technologies.
About Kinetic Technologies
Kinetic Technologies designs, develops and markets proprietary high-performance analog and mixed-signal semiconductors across consumer, computer, communications, industrial, automotive and enterprise markets. Along with designing power products to protect, regulate, and monitor power consumption, Kinetic also produces products that switch, transform, and protect high resolution audio, video, and data signals. Applications can include smartphones, notebook/Chromebook and accessories, as well as serving a wide range of industrial, automotive, and enterprise solutions. Kinetic Technologies has R&D centers in Silicon Valley and Asia, with operations and logistics based in Asia and Europe. For more information, please visit http://www.kinet-ic.com/ .
*Kinetic Technologies logo is a trademark of Kinetic Technologies. All other brand and product names appearing in this document are the property of their respective holders.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220612005029/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom